Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose–effect of cisatracurium on intraoperative neurophysiological monitoring in brain tumor surgery
ChiCTR2500102327Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Jinan University
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of cisatracurium in Intracranial mass lesion (IML) (3 arms), sponsored by First Affiliated Hospital of Jinan University. Primary endpoints: Motor Evoked Potential (MEP) and Somatosensory Evoked Potential (SEP). Planned start May 2025; status: not yet recruiting.
02
Drugs
cisatracurium
03
Conditions
Intracranial mass lesion (IML)
Beyond the preview
Go deeper on ChiCTR2500102327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102327.